Contrarian Corpus
Muddy Waters vs. Chinook Therapeutics Inc

Chinook Therapeutics Inc · KDNY

1 deck published between 2023-05-16 and 2023-05-16 — 36 pages, 36 analysed slides total.

initial thesis

Timeline

Each deck in chronological order — click to open. This is the story of the campaign as it unfolded.

  1. 2023-05-16 initial thesis

    2023 05 MW_KDNY_20230516

    36pp · research_note

    Muddy Waters is short Chinook (KDNY): lead drug atrasentan is inefficacious, harmful, and blocked by sparsentan's IgAN orphan-drug exclusivity — FDA approval is highly unlikely.